Vanda Pharmaceuticals Inc. News
Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
The presentation will take place as part of the 2008 Bank of America Healthcare Conference at the Four Seasons,
To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fanapta(TM) (iloperidone), for which Vanda has recently submitted an NDA to the FDA, is a compound for the treatment of schizophrenia. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic primary insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
SOURCE Vanda Pharmaceuticals Inc.
Search Our News Using Google Search
Can't find what you want? Try using Google:
